BVF Partners

Founded 1993

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 31
Average round size
info
The average size of a deal this fund participated in
$73M
Portfolio companies 35
Rounds per year 1.11
Lead investments 5
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.03
Exits 21
Key employees Soon

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Biopharma
Summary

The leading representative office of defined Corporate Investor is situated in the San Francisco. The venture was found in North America in United States.

The usual cause for the fund is to invest in rounds with 5 partakers. Despite the BVF Partners, startups are often financed by Purdue Pharma, Versant Ventures, MPM Capital. The meaningful sponsors for the fund in investment in the same round are Versant Ventures, Wellington Management, Surveyor Capital.

Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Repare Therapeutics. For fund there is no match between the location of its establishment and the land of its numerous investments - Canada. Among the most successful fund investment fields, there are Health Care, Pharmaceutical.

The important activity for fund was in 2019. Deals in the range of 50 - 100 millions dollars are the general things for fund. The fund is generally included in 2-6 deals every year.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of BVF Partners:
There are no funds here. If we find new data, we will add it here.
Typical Co-investors
BVF Partners is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after BVF Partners:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Point Biopharma

Biopharma
Biotechnology
Therapeutics
$165M01 Jul 2021 Indianapolis, Indiana, United States

KAHR medical

Biotechnology
Medical
Pharmaceutical
$46M16 Jun 2021 Jerusalem, Jerusalem District, Israel

Numab

Biopharma
Biotechnology
Health Diagnostics
Life Science
Medical
Therapeutics
$109M19 May 2021 Zurich, Switzerland

Alpha9 Theranostics

Biotechnology
Medical
Product Research
$8M28 Apr 2021 Vancouver, British Columbia, Canada

Biotechnology
Health Care
Medical
$63M15 Apr 2021 California, United States

Viracta Therapeutics

Biopharma
Biotechnology
Medical
Pharmaceutical
Therapeutics
$65M24 Feb 2021 California, United States

Biotechnology
Health Care
Information Technology
Medical
Therapeutics
$45M18 Feb 2021 London, England, United Kingdom

Day One Biopharmaceuticals

Biopharma
Biotechnology
Health Care
Pharmaceutical
$130M10 Feb 2021 South San Francisco, California, United States

Shoreline Biosciences

Biotechnology
Life Science
Medical
$43M07 Feb 2021 San Diego, California, United States
News
ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform

– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.

HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate

– HilleVax, Inc. (HilleVax), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, announced the close of a $135 million crossover financing led by Frazier Healthcare Partners and joined by RA Capital Management, Deerfield Management Company, Abingworth, Lightspeed Venture Partners, Perceptive Advisors, Catalys Pacific, Samsara BioCapital, BVF Partners, Qiming Venture Partners USA, Greenspring Associates, Richard King Mellon Foundation, and Sahsen Ventures.
– The proceeds of this financing support the further clinical development of HilleVax’s virus-like particle (VLP) based vaccine candidate, HIL-214, for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent BVF Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: